Evaluating Fluid Strategies in Thoracic Surgery Patients Utilizing a Goal Directed Approach
Primary Purpose
Hypotension, Kidney Injury
Status
Completed
Phase
Phase 4
Locations
United States
Study Type
Interventional
Intervention
Plasmalyte 3ml/kg/hr group
Plasmalyte 6ml/kg/hr group
Sponsored by
About this trial
This is an interventional treatment trial for Hypotension focused on measuring Hypotension, Kidney injury
Eligibility Criteria
Inclusion Criteria:
- between 18-89 years of age
- undergoing pulmonary lobectomy with open or video assisted thoracotomy
Exclusion Criteria:
- patient refusal
- pregnancy
- cardiac arrhythmia
- pacemaker dependency
- severe aortic insufficiency
- idiopathic hypertrophic subaortic stenosis
- prisoners
- decisionally challenged
- patients that refuse to receive intravenous fluid products made from human plasma (Albumin 5%)
- patients with skin infection or breakdown on their fingers
- severe peripheral vascular disease
- evidence of compromised finger perfusion will be excluded
Sites / Locations
- University of Colorado Hospital
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Active Comparator
Arm Label
Plasmalyte 3ml/kg/hr group
Plasmalyte 6ml/kg/hr group
Arm Description
Outcomes
Primary Outcome Measures
Development of Renal Injury
Acute renal injury as defined by the American Kidney Injury Network (AKIN) criteria in the first 72 hours postoperatively (serum creatinine levels). The AKIN scale will be used to assess the presence and severity of acute kidney injury (AKI). The AKIN is a classification/staging system of acute kidney injury developed by the Acute Kidney Injury Network which uses changes in serum creatinine (SCr) and urine output to assess AKI. Stages of acute kidney injury are defined as 1, 2, or 3, with 3 indicating the most severe AKI.
(1) Increase ≥ 0.3 mg per dL (26.52 μmol per L) or ≥ 1.5- to twofold from baseline. (2) Increase > two- to threefold from baseline. (3) Increase > threefold from baseline or ≥ 4.0 mg per dL (353.60 μmol per L) with an acute rise of at least 0.5 mg per dL (44.20 μmol per L).
Development of Pulmonary Edema
The number of participants diagnosed with mild to severe pulmonary edema at any time up to 72 hours after surgery is reported.
Secondary Outcome Measures
Length of Surgical Intensive Unit Stay/Hospital Stay
Length of Surgical Intensive Unit Stay/Hospital Stay
Removal of Chest Tubes
Time to removal of Chest Tubes
Development of Morbidity
Development of Morbidity, including: acute lung injury, Acute Respiratory Distress, Deep Vein Thrombus, infection, delirium
Death
Death
Full Information
NCT ID
NCT02135146
First Posted
May 6, 2014
Last Updated
February 24, 2020
Sponsor
University of Colorado, Denver
1. Study Identification
Unique Protocol Identification Number
NCT02135146
Brief Title
Evaluating Fluid Strategies in Thoracic Surgery Patients Utilizing a Goal Directed Approach
Official Title
Evaluating Fluid Strategies in Thoracic Surgery Patients Utilizing a Goal Directed Approach
Study Type
Interventional
2. Study Status
Record Verification Date
February 2020
Overall Recruitment Status
Completed
Study Start Date
January 2014 (undefined)
Primary Completion Date
September 2016 (Actual)
Study Completion Date
September 2016 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of Colorado, Denver
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The purpose of this study is to conduct a prospective, randomized, controlled trial comparing a restrictive vs. conservative fluid strategy in thoracic surgery patients. Excessive perioperative fluid has been retrospectively implicated in the development postoperative acute lung injury (PALI) and pulmonary edema following lung resection. However, fluid restriction in these patients is not without risk and may compromise end organ perfusion (i.e. acute kidney injury). The hypothesis is that a conservative fluid approach in thoracic surgery patients will result in better end organ perfusion with fewer occasions of acute kidney injury (AKI) without causing an increase in postoperative acute lung injury or pulmonary edema.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypotension, Kidney Injury
Keywords
Hypotension, Kidney injury
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
Outcomes Assessor
Allocation
Randomized
Enrollment
40 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Plasmalyte 3ml/kg/hr group
Arm Type
Active Comparator
Arm Title
Plasmalyte 6ml/kg/hr group
Arm Type
Active Comparator
Intervention Type
Drug
Intervention Name(s)
Plasmalyte 3ml/kg/hr group
Intervention Description
This group will have intravenous plasmalyte fluid limited to a rate of 3 ml/kg/hr. and a nexfin monitor placed on them
Intervention Type
Drug
Intervention Name(s)
Plasmalyte 6ml/kg/hr group
Intervention Description
This group will have intravenous plasmalyte fluid limited to a rate of 6 ml/kg/hr. and a Nexfix Monitor placed on them
Primary Outcome Measure Information:
Title
Development of Renal Injury
Description
Acute renal injury as defined by the American Kidney Injury Network (AKIN) criteria in the first 72 hours postoperatively (serum creatinine levels). The AKIN scale will be used to assess the presence and severity of acute kidney injury (AKI). The AKIN is a classification/staging system of acute kidney injury developed by the Acute Kidney Injury Network which uses changes in serum creatinine (SCr) and urine output to assess AKI. Stages of acute kidney injury are defined as 1, 2, or 3, with 3 indicating the most severe AKI.
(1) Increase ≥ 0.3 mg per dL (26.52 μmol per L) or ≥ 1.5- to twofold from baseline. (2) Increase > two- to threefold from baseline. (3) Increase > threefold from baseline or ≥ 4.0 mg per dL (353.60 μmol per L) with an acute rise of at least 0.5 mg per dL (44.20 μmol per L).
Time Frame
Post-op up to 72 hours
Title
Development of Pulmonary Edema
Description
The number of participants diagnosed with mild to severe pulmonary edema at any time up to 72 hours after surgery is reported.
Time Frame
Post-op up to 72 hours
Secondary Outcome Measure Information:
Title
Length of Surgical Intensive Unit Stay/Hospital Stay
Description
Length of Surgical Intensive Unit Stay/Hospital Stay
Time Frame
Up to 7 days
Title
Removal of Chest Tubes
Description
Time to removal of Chest Tubes
Time Frame
Post-op up to 48 hours
Title
Development of Morbidity
Description
Development of Morbidity, including: acute lung injury, Acute Respiratory Distress, Deep Vein Thrombus, infection, delirium
Time Frame
Up to 7 days
Title
Death
Description
Death
Time Frame
Assessed up to 30 days Post-op
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
89 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
between 18-89 years of age
undergoing pulmonary lobectomy with open or video assisted thoracotomy
Exclusion Criteria:
patient refusal
pregnancy
cardiac arrhythmia
pacemaker dependency
severe aortic insufficiency
idiopathic hypertrophic subaortic stenosis
prisoners
decisionally challenged
patients that refuse to receive intravenous fluid products made from human plasma (Albumin 5%)
patients with skin infection or breakdown on their fingers
severe peripheral vascular disease
evidence of compromised finger perfusion will be excluded
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Tamas Seres, M.D., PH.D.
Organizational Affiliation
University of Colorado, Denver
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Colorado Hospital
City
Aurora
State/Province
Colorado
ZIP/Postal Code
80138
Country
United States
12. IPD Sharing Statement
Learn more about this trial
Evaluating Fluid Strategies in Thoracic Surgery Patients Utilizing a Goal Directed Approach
We'll reach out to this number within 24 hrs